Enterosys technology and R&D pipeline

ENTEROSYS specificity is to go a step further in treatment of T2 diabetes.

While current drugs focus mainly on glucose management, ENTEROSYS regulates glucose uptake by intestine as it is done in normal conditions.
Another important advantage of our technology is act locally in the intestine, thus not having systemic effect.
This approach comes from decades of expertise and mastering of very specific technologies to enable this scientific expertise.

Molecular mechanisms through which the gut-brain axis is controlling physiological outcomes such as the glycaemic and gastrointestinal physiology.

The ENTEROSYS concept

Local action, central reaction, global effects

Then, the scientists discovered that hyper-contractility of the intestine in type 2 diabetes break the glycaemia regulation loop.
As a matter of fact, hyper-contractility generates antinomic effects leading to hyperglycaemia:

  • it increases glucose absorption;
  • it generates an afferent signal informing the brain to block glucose entry in tissues (insulin resistance).

And while hyper-contractility remains temporary at the beginning of meals in normal conditions to avoid immediate absorption, it is permanent for in type 2 diabetes conditions.

Technology 1

Intestine contraction analysis

This technology brings two major innovations:

  • measurement of intestinal contractions in real-time in physiological and pathological conditions,
  • identification of new molecular actors involved in the “gut-to-brain” axis that controls glucose homeostasis.

 This technology allows to us to identify new molecular agents with a therapeutic potential that are present in the intestine or in food, are different in their nature and have multiple physiological functions.

Technology 2

ROS: Hydrogen Peroxide and RNS: Nitric Oxide real-time measurement

What is commonly known is that Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) are two biomarkers that reflect physiological effects: regulation, protection and toxicity. What is commonly known is that Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) are two biomarkers that reflect physiological effects: regulation, protection and toxicity.

This technology brings two major benefits:

  • identification of pathways in physiological and pathological states;
  • identification of targeted tissues and cells.

As a matter of fact, this technology has proven results in:

  • in real-time in all experimental conditions: In vitro, ex vivo or in vivo measurements;
  • a large set of tissues: Hypothalamus, Heart, Adipose tissue, Liver, Kidney, Smooth Muscle, Gut / intestine.